Dr. Jeffrey Silva explores the role of mass spectrometry-based proteomics on drug discovery, disease mechanisms, and biomarker identification.
Drug discovery and development is a complex and challenging process that requires the identification and characterization of novel drug targets. Proteomics, the large-scale analysis of proteins, is an increasingly important tool in this effort, providing a powerful means to understand disease mechanisms, discover biomarkers, and profile drug pharmacology. Mass spectrometry, a key technology in proteomics, offers high resolution, reproducible and actionable data on a wide range of protein targets.
In this webinar, Jeffrey Silva, PhD, a Principal Scientist in the Proteomics Group at Cell Signaling Technology provides an overview of how mass spectrometry-based proteomics can be used for drug discovery and development. Jeffrey also presents several case studies highlighting how these techniques can be used to gain a deeper understanding of disease mechanisms and as a powerful tool for drug discovery.
Who Should Attend?
- Searching for diagnostic proteomic biomarkers to monitor drug efficacy or disease progression
- Trying to identify on- & off-target effects of small molecule inhibitors or PROTAC-mediated degradation
- Identifying critical signaling pathways modulated upon compound treatment or onset of disease
Presenters
Jeffrey C. Silva
Dr. Jeffrey Silva is a highly experienced scientist with a diverse background. He earned his bachelor's degree in chemistry and biochemistry from Merrimack College, and his PhD from Johns Hopkins University, where he researched aflatoxin biosynthesis in Aspergillus. After completing a postdoctoral fellowship at Harvard Medical School, Dr. Silva joined Microbia, a Biotech start-up, where he worked on engineering microbial organisms to overproduce natural products. He then joined Waters Corporation, where he helped develop a novel application for global protein analysis using liquid chromatography and high-resolution mass spectrometry.
In 2005, Dr. Silva joined Cell Signaling Technology to lead a Proteomics service group, using unique immuno-affinity capture reagents with LC-MS to probe cellular signaling and protein post-translational modifications for drug discovery and disease biology. More recently, he served as Chief Technology Officer at Adeptrix Corporation, where he developed a microarray technology platform for targeted proteomics. Dr. Silva has now returned to Cell Signaling Technology as a Principal Scientist in the Proteomics group, where he continues to integrate immunoaffinity reagents with mass spectrometry for translational research.
Sponsor
Cell Signaling Technology Inc.
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
